Next Article in Journal
Antibacterial and Antifungal Management in Relation to the Clinical Characteristics of Elderly Patients with Infective Endocarditis: A Retrospective Analysis
Next Article in Special Issue
Controlling of Bacterial Virulence: Evaluation of Anti-Virulence Activities of Prazosin against Salmonella enterica
Previous Article in Journal
Effectiveness of Intramammary Antibiotics, Internal Teat Sealants, or Both at Dry-Off in Dairy Cows: Clinical Mastitis and Culling Outcomes
Previous Article in Special Issue
Characterization of Diarreaghenic Escherichia coli Strains Isolated from Healthy Donors, including a Triple Hybrid Strain
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Antibiotics
Volume 11
Issue 7
10.3390/antibiotics11070955
antibiotics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Whole-Genome Sequencing of ST2 A. baumannii Causing Bloodstream Infections in COVID-19 Patients

by
Sabrina Cherubini
1,
Mariagrazia Perilli
1,
Bernardetta Segatore
1,
Paolo Fazii
2,
Giustino Parruti
3,
Antonella Frattari
4,
Gianfranco Amicosante
1 and
Alessandra Piccirilli
1,*
1
Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, 67100 L’Aquila, Italy
2
Clinical Microbiology and Virology Unit, Spirito Santo Hospital, 65122 Pescara, Italy
3
Infectious Diseases, Spirito Santo Hospital, 65122 Pescara, Italy
4
Intensive Care Unit, Spirito Santo Hospital, 65122 Pescara, Italy
*
Author to whom correspondence should be addressed.
Antibiotics 2022, 11(7), 955; https://doi.org/10.3390/antibiotics11070955
Submission received: 1 July 2022 / Revised: 14 July 2022 / Accepted: 15 July 2022 / Published: 15 July 2022
(This article belongs to the Special Issue Bacterial Pathogenesis and Antimicrobial Strategy)
Versions Notes

Abstract

:
A total of 43 A. baumannii strains, isolated from 43 patients affected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and by bacterial sepsis, were analyzed by antimicrobial susceptibility testing. All strains were resistant to almost three different classes of antibiotics, including carbapenems and colistin. The whole-genome sequencing (WGS) of eight selected A. baumannii isolates showed the presence of different insertion sequences (ISs), such as ISAba13, ISAba26, IS26, ISVsa3, ISEc29, IS6100 and IS17, giving to A. baumannii a high ability to capture and mobilize antibiotic resistance genes. Resistance to carbapenems is mainly mediated by the presence of OXA-23, OXA-66 and OXA-82 oxacillinases belonging to OXA-51-like enzymes. The presence of AmpC cephalosporinase, ADC-25, was identified in all A. baumannii. The pathogenicity of A. baumannii was exacerbated by the presence of several virulence factors. The multi-locus sequence typing (MLST) analysis showed that all strains belong to sequence type 2 (ST) international clone.

1. Introduction

Acinetobacter baumannii belongs to a group of nosocomial pathogens, designated by the acronym “ESKAPE” (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp.). These bacteria are the predominant cause of life-threatening nosocomial infections in critically ill and immunocompromised patients worldwide. ESKAPE pathogens have developed resistance mechanisms against almost all antimicrobial agents, including carbapenems, the last line of defense in clinical armamentarium [1,2,3,4]. A. baumannii is commonly associated with nosocomial infections including bacteremia, endocarditis, urinary tract infections (UTIs), meningitis, gastrointestinal and skin/wound infections [5,6,7,8]. However, community-acquired A. baumannii infections have been described, in particular, in people with comorbidities [9,10,11]. Several studies have reported that respiratory viral infections, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), predispose patients to bacterial co-infections and secondary infections [12]. Prolonged hospitalization in the intensive care unit (ICU) may be linked with increased possibility of developing bacterial co-infection, especially with multi-drug resistant (MDR) A. baumannii in critically ill coronavirus disease 2019 (COVID-19) patients. Generally, antibiotic resistance in A. baumannii is due to different mechanisms: (a) inactivation of antibiotics by enzymatic hydrolysis (i.e., β-lactamases), (b) reducing membrane permeability, (c) increasing efflux of antibiotics (i.e., overexpression of drug efflux pumps) and (d) mutations in antibiotic binding targets by genetic insertion sequences. Since 1990, carbapenems have been the mainstay antibiotics in the treatment of A. baumannii infections. Currently, carbapenem-resistant A. baumannii (CRAb) poses a global threat to human health. CRAb is emerging worldwide, and the majority of these isolates often show MDR or extensive drug resistant (XDR) patterns [13,14]. In 2018, the World Health Organization (WHO) considered A. baumannii a priority for the research and development of new antibiotics [3]. The presence of β-lactamases, in particular oxacillinases (OXAs), constitutes the main mechanism of resistance to carbapenems in A. baumannii. The main bla genes found in A. baumannii are represented by the presence of intrinsic chromosomal blaOXA-51-like genes and other groups of OXA acquired carbapenemases, including OXA-23-like, OXA-24/40-like, OXA-58-like, and OXA-143 enzymes [15]. In a large number of studies, ISAba1 has been identified in combination with different OXA-β-lactamases, including the blaOXA−51-like genes. This insertion sequence is located upstream in the opposite direction of blaOXA−51-like, acting as a promoter [16]. Among other β-lactamases, class A β-lactamases (e.g., PER-1, VEB-1, CTX-M-1, TEM-1), metallo β-lactamases (e.g., IMP, VIM, NDM) and AmpC cephalosporinases are prevalent in A. baumannii [17,18]. A. baumannii is also able to promote antibiotic resistance by virulence factors such as outer membrane protein modification, cell envelope factors, enzymes, quorum sensing, biofilm formation, motility and micronutrient acquisition systems [19]. Currently, very few therapeutic agents exist or are in development to treat MDR A. baumannii infections. Indeed, the ability of A. baumannii to persist and easily survive on biotic and abiotic surfaces and under dry conditions makes its treatment and eradication really complicated [20]. Because of the decrease in susceptibility to a wide range of antibiotics, the treatment options are frequently limited to synergistic use of these agents. Despite its nephrotoxicity, colistin, as monotherapy or in combination with other active compounds, has been used in critically ill patients [21]. Unfortunately, colistin-resistant Acinetobacter strains have rapidly emerged [22,23,24]. In recent times, cefiderocol, a novel siderophore cephalosporin, and durlobactam were approved for the treatment of MDR Gram-negative infections, including A. baumannii [25,26,27]. The aim of the present study was to explore, by whole-genome sequencing (WGS), antibiotic resistance genes (ARGs) and virulence factors of A. baumannii strains isolated from COVID-19 patients affected by sepsis and admitted to the ICU of Spirito Santo Hospital, Pescara, Central Italy.

2. Results

2.1. Minimal Inhibitory Concentrations (MICs)

A total of 43 A. baumannnii strains, isolated from positive blood cultures, were analyzed against a panel of antibiotics. All the strains showed the same antimicrobial susceptibility profile with a remarkable resistance to amikacin (MIC ≥ 64 mg/L), gentamicin (MIC ≥ 16 mg/L), ciprofloxacin (MIC ≥ 4 mg/L), meropenem (MIC > 8 mg/L), colistin (MIC > 8 mg/L) and trimethoprim–sulfamethoxazole association (MIC > 160 mg/L).

2.2. WGS and Multi-Locus Sequence Typing (MLST)

The WGS was performed on eight non-replicative A. baumannii strains isolated from patients admitted to ICU in different time periods. By molecular analysis we identified the sequence type (MLST), ARGs, virulence factors and mobile genetic elements (MGEs) harbored in the analyzed genome of A. baumannii. The genome size of the eight A. baumannii strains ranged from 3.8 to 4.0 Mb, and no plasmids were found. The MLST analysis using the Pasteur scheme revealed that all isolates belonged to the ST2 sequence type (Table 1).

2.3. Antimicrobial Resistance Genes (ARGs)

The A. baumannii isolates showed a wide variety of antibiotic resistance genes, mobile genetic elements (e.g., IS, sequence insertion) and several virulence factors (Table 1).

2.3.1. β-Lactam Resistance Genes

The A. baumannii strains analyzed in this study harbored molecular class C and class D β-lactamases. Overall, blaADC-25 and blaOXA-23 genes were found in all isolates with a co-presence of blaOXA-66 (four out of eight isolates) or blaOXA-82 (four out of eight isolates) (Table 1). Both blaOXA-66 and blaOXA-82 belong to the constitutive blaOXA-51-type genes. The OXA-82 enzyme differs from OXA-66 only by one amino acid residue. The leucine 157 (L157) in OXA-66 is replaced by valine (V157) in OXA-82.

2.3.2. Aminoglycoside Resistance Genes

In 100% of A. baumannii, resistance to aminoglycosides was mediated by aadA1, aacA4 and armA genes with the presence of the bi-functional gene aac(6′)Ib-cr. The armA gene confers resistance to gentamicin and amikacin, and it is generally plasmid-mediated. In four isolates we found the presence of other genes conferring resistance to aminoglycosides, such as aph(3′)-IVa, aacA2, aadB, aac(3′)-Ic and aac(3)-Ia (Table 1).

2.3.3. Fluoroquinolone Resistance Genes

Resistance to fluoroquinolones is mediated by the aac(6′)Ib-cr gene, a bi-functional gene which confers resistance to both fluoroquinolones and aminoglycosides (Table 1).

2.3.4. Other Antimicrobial Resistance Genes

The mph(E) and msr(E) (macrolide resistance), sul1 (sulphonamide resistance), tet(B) (tetracycline resistance) and catB8 (chloramphenicol resistance) genes were also detected in all A. baumannii isolates. The strA/strB genes, which confer resistance to streptomycin, were identified in 50% of the analyzed strains (Table 1).

2.4. Mobile Genetic Elements (MGEs)

A wide variety of sequence insertions (ISs) and transposon elements were identified in all analyzed strains (Table 1). In detail, transposon Tn6207 was found in 3 A. baumannii isolates. Sequence insertion elements such as ISAba2 of 1308bp length (3 isolates), ISAba13 of 1039 bp length (4 isolates), ISAba26 of 1318 bp length (4 isolates), IS26 of 820 bp length (1 isolate), ISVsa3 of 977 bp (3 isolates), ISEc29 of 1325 bp (7 isolates), IS6100 of 880 bp (4 isolates) and IS17 of 1040 bp (4 isolates) were identified in the genome of A. baumannii.

2.5. Virulence Factors and Other Mechanisms of Resistance

Virulome analysis allowed to identify genes involved in biofilm (bap and pgaABCD locus) and pili (csu) formation. The ompA porin, lipid A synthesis (lpxABCDLM locus), biosynthesis of the LPS core (lpsB), serum resistance (pbpG), phospholipase C and D (plc and plcD), LysR-type transcriptional regulator as well as acinetobactin genes cluster (bau, bas, bar, ent) were found in all ST2 A. baumannii isolates (Table 2). The resistance-nodulation-cell division efflux pump genes (RND: adeFGH) were also found in the totality of the analyzed strains. The gene hemO, related to iron uptake, and the catalase gene (katA), which protects bacteria from superoxidants produced by leukocytes as a host defense mechanism, were also present in all sequenced strains.

3. Discussion

In this study, we used WGS to retrospectively investigate the resistance mechanisms in carbapenem- and colistin-resistant A. baumannii isolates in COVID-19 patients admitted to the ICU of Spirito Santo Hospital, Pescara (Central Italy). Analysis of the sequenced genomes revealed that all isolates shared the same MLST sequence type (ST2), which is the representative ST type of global clone II [28]. To date, the international clone ST2 is the most dominant type globally detected in all A. baumannii genomes sequenced [29]. Several studies showed the dissemination of CRAb isolates harboring the blaOXA-23-like and belonging to ST2 from different countries [30]. As reported in previous studies, blaOXA-23 was the most widely reported gene, and blaOXA-66 was the most common variant of OXA enzymes [31]. In our strains, the OXA-23 class D carbapenemase was identified in association with OXA-66 or OXA-82. The OXA-66 and OXA-82, which differ each other by L167V substitution, belong to the OXA-51-like enzymes. The OXA-51 is intrinsically over-expressed and it is able to confer high resistance to carbapenems in A. baumannii isolates [32]. The increased antibiotic resistance in A. baumannii is largely due to the actions of mobile genetic elements, to the activation of intrinsic resistance mechanisms, such as the chromosomal β-lactamase blaADC, and to the presence of efflux pumps [33]. In our study we found the presence of an AmpC enzyme, the ADC-25 cephalosporinase, and the AdeFGH RND efflux pumps in all A. baumannii strains. To our knowledge, the AdeFGH RND efflux pumps seem to play a major role in acquired resistance and may also be associated with carbapenem non-susceptibility in A. baumannii [34,35].
The pathogenicity of A. baumannii isolates analyzed in the present study is exacerbated by the presence of the abaI/abaR quorum sensing system which is involved in morphology, growth characteristics, biofilm formation, motility, resistance and virulence of these microorganisms [36]. In addition, in our A. baumannii we found two-component signal transduction system BfmRS, which seem to be implicated in the control of various virulence-related traits and acting as a global modulator of A. baumannii physiology [37,38]. It is well known that, A. baumannii showing a loss of BfmS results in a significant reduction of motility [39]. A. baumannii represents a serious problem for public health because of its intrinsic and acquired antimicrobial resistance determinants and pathogenicity factors. The main types of mobile elements involved in the capture and mobilization of ARGs in Gram-negative pathogens, including A. baumannii, is represented by gene cassettes, transposons and sequence insertions (ISs) [40]. These mobile structures could disseminate antibiotic resistance determinants between pathogens compromising antibiotic treatment [41,42]. In the present study, we found a wide variety of ISs belonging to different IS families such as IS3 (ISAba2), IS4 (ISEc29), IS5 (IS17 and ISAba13), IS6 (IS26 and IS6100), IS30 (ISAba125), IS91 (ISVsa3) and IS256 (ISAba26). Generally, two copies of the same or related ISs can move resistance genes as part of a composite transposon, and some of the ISs include a strong promoter that drives expression of the captured gene [41]. The ISAba1 was first identified in A. baumannii upstream of blaOXA-23, blaOXA-51, blaOXA-58 and blaADC-genes, and it seems to be an important factor in the genetic plasticity of this microorganism [43,44]. The presence of ISAba1 upstream of blaOXA-51-like genes might represent a real mechanism of carbapenem resistance [45]. Insertion of ISAba125 in the blaOXA-23 promoter sequence has been reported to be associated with overexpression of blaOXA-23, blaOXA-51 and carbapenem resistance phenotypes in A. baumannii [46]. In all analyzed strains we also found gene structures indicating the presence of the Tn6207 transposon. Tn6207 is a composite transposon containing a tetracycline efflux pump and its regulator genes tetB and aminoglycoside resistance genes strB and strA.
Respiratory viral infections, such as SARS-CoV-2, predispose patients to bacterial co-infections and secondary infections [47,48,49,50]. This represents a high risk for hospitalized patients. In some patients we have ascertained the co-presence of other microorganisms such as K. pneumoniae. Bloodstream CRAb and K. pneumoniae remain one of the most common ICU-acquired infections [50,51,52].

4. Materials and Methods

4.1. Strains Selection and Identification

A total of 43 A. baumannii strains were isolated from bloodstream infection of 43 COVID-19 patients with evident clinical signs of bacterial sepsis. The patients were admitted to the ICU ward of Spirito Santo Hospital (Pescara, Central Italy). Overall, 32 (74%) patients were male and 11 (26%) were female, with an age ranging from 31 to 82 years old. These patients had comorbidities such as kidney disease, diabetes, hypertension, or heart disease, and in some of them a co-presence of E. faecalis, S. marcescens and K. pneumoniae was also ascertained. The blood sample collection was repeated with an interval of 2 days for each patient. All samples were transferred to clinical molecular laboratory and analyzed following methods according to Clinical and Laboratory Standards Institute (CLSI) guidelines [53]. One A. baumannii strain per patient was included in the study. The strains, selected from positive cultures, were grown in Cled agar plates (Oxoid, UK) at 37 °C, overnight, and identified by matrix-assisted laser desorption ionization–time of flight (MALDI-TOF) mass spectrometry (Bruker Daltonics, Billerica, MA, USA).

4.2. Antimicrobial Susceptibility

Antimicrobial susceptibility was determined by the Phoenix system (Becton, Dickinson and Company, Sparks, MD, USA) at Clinical Microbiology and Virology Unit, Spirito Santo Hospital, Pescara, Italy. The MICs for amikacin, gentamicin, ciprofloxacin, meropenem, colistin and trimethoprim–sulfamethoxazole association were also performed by conventional broth microdilution procedures in Mueller–Hinton broth (Biolife Italiana, Milan, Italy) supplemented with calcium and magnesium (CAMHB), using an inoculum of 5 × 105 CFU/mL according to CLSI [54].

4.3. WGS

A total of eight representative A. baumannii clinical strains, named PE/1-PE/8, were included in the genome sequencing. Total DNA was extracted using MagMax Microbiome Ultra Nucleic Acid Isolation kit (Applied Biosystems and ThermoFisher Scientific, Monza, Italy), according to the manufacturer’s instructions. Library preparation was performed as previously reported [55,56]. Sequencing of the library was carried out on an Illumina MiSeq using a paired-end 600-cycle protocol with a read length of 300 bp. DRAGEN FastQC + MultiQC v3.6.3 (https://basespace.illumina.com/apps/10562553/DRAGEN-FastQC-MultiQC, access date: 31 January 2022) were used for quality control and sequences filtering. Paired-end reads were assembled with Velvet v1.2.10 (https://basespace.illumina.com/apps/8556549/Velvet-de-novo-Assembly, access date: 21 February 2022). Multi-locus sequence typing (MLST) on assembled A. baumannii genomes was performed utilizing the Pasteur scheme. This scheme includes the identification of seven internal housekeeping genes: citrate synthase (gltA), homologous recombination factor (recA), 60-kDa chaperonin (cpn60), elongation factor EF-G (fusA), CTP synthase (pyrG), 50S ribosomal protein L2 (rplB) and RNA polymerase subunit B (rpoB) [57]. ResFinder4.1 and MobileElementFinder 1.0.3 were used to detect acquired antimicrobial resistance genes and mobile genetic elements, respectively (http://www.genomicepidemiology.org, accessed on 28 February 2022). Virulence Factor Database (VFDB) was used for the detection of virulence genes (http://www.mgc.ac.cn/VFs/, accessed on 4 March 2022).

5. Conclusions

In the present study all A. baumannii were isolated from patients which developed a bloodstream infection. A detailed molecular characterization of resistomes, including ARGs and MGEs, and virulence factor analysis were performed on the eight ST2 A. baumannii clinical isolates. This WGS analysis remarks the importance to know the genetic background of clinical pathogens. The use of a rapid method, such as next-generation sequencing, to identify resistomes and virulomes in clinical settings could be useful for an effective antimicrobial stewardship program.

Author Contributions

Conceptualization, M.P. and A.P.; methodology, S.C. and B.S.; investigation, S.C., A.P. and B.S.; data curation, A.P., S.C. and M.P.; writing—original draft preparation, A.P. and M.P.; writing—review and editing, M.P., A.P., G.A. and B.S.; visualization, P.F., G.P. and A.F.; supervision, A.P. and M.P.; project administration, M.P. and A.P.; funding acquisition, A.P. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by University of L’Aquila, grant number (07_PROGETTO_RICERCA_ATENEO).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Acknowledgments

The authors wish to thank Anna Toso (Toronto Catholic District School Board, Toronto, Canada) for the language revision of the manuscript.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Mulani, M.S.; Kamble, E.; Kumkar, S.N.; Tawre, M.S.; Pardesi, K.R. Emerging strategies to combat ESKAPE pathogens in the era of antimicrobial resistance: A review. Front. Microbiol. 2019, 10, 539. [Google Scholar] [CrossRef]
  2. Mancuso, G.; Midiri, A.; Gerace, E.; Biondo, C. Bacterial antibiotic resistance: The most critical pathogens. Pathogens 2021, 10, 1310. [Google Scholar] [CrossRef] [PubMed]
  3. Tacconelli, E.; Carrara, E.; Savoldi, A.; Harbarth, S.; Mendelson, M.; Monnet, D.L.; Pulcini, C.; Kahlmeter, G.; Kluytmans, J.; Carmeli, Y.; et al. Discovery, research, and development of new antibiotics: The WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect. Dis. 2018, 18, 318–327. [Google Scholar] [CrossRef]
  4. De Oliveira, D.M.P.; Forde, B.M.; Kidd, T.J.; Harris, P.N.A.; Schembri, M.A.; Beatson, S.A.; Paterson, D.L.; Walker, M.J. Antimicrobial resistance in ESKAPE pathogens. Clin. Microbiol. Rev. 2020, 33, e00181-19. [Google Scholar] [CrossRef] [PubMed]
  5. Andersen, C.T.; Langendorf, C.; Garba, S.; Sayinzonga-Makombe, N.; Mambula, C.; Mouniaman, I.; Hanson, K.E.; Grais, R.F.; Isanaka, S. Risk of community- and hospital-acquired bacteremia and profile of antibiotic resistance in children hospitalized with severe acute malnutrition in Niger. Int. J. Infect. Dis. 2022, 119, 163–171. [Google Scholar] [CrossRef]
  6. Wu, D.; Huang, Y.; Ding, J.; Jia, Y.; Liu, H.; Xiao, J.; Peng, J. Impact of carbapenem-resistant Acinetobacter baumannii infections on acute pancreatitis patients. Pancreatology 2022, 22, 194–199. [Google Scholar] [CrossRef] [PubMed]
  7. Rao, S.; Betancourt-Garcia, M.; Kare-Opaneye, Y.O.; Swierczewski, B.E.; Bennett, J.W.; Horne, B.; Fackler, J.; Suazo Hernandez, L.P.; Brownstein, M.J. Critically ill patient with multidrug-resistant Acinetobacter baumannii respiratory infection successfully treated with intravenous and nebulized bacteriophage therapy. Antimicrob. Agents Chemother. 2022, 66, e0082421. [Google Scholar] [CrossRef] [PubMed]
  8. Martinez, J.; Razo-Gutierrez, C.; Le, C.; Courville, R.; Pimentel, C.; Liu, C.; Fung, S.E.; Tuttobene, M.R.; Phan, K.; Vila, A.J.; et al. Cerebrospinal fluid (CSF) augments metabolism and virulence expression factors in Acinetobacter baumannii. Sci. Rep. 2021, 11, 4737. [Google Scholar] [CrossRef]
  9. Xu, A.; Zhu, H.; Gao, B.; Weng, H.; Ding, Z.; Li, M.; Weng, X.; He, G. Diagnosis of severe community-acquired pneumonia caused by Acinetobacter baumannii through next-generation sequencing: A case report. BMC Infect. Dis. 2020, 20, 45. [Google Scholar] [CrossRef]
  10. Chen, C.T.; Wang, Y.C.; Kuo, S.C.; Shih, F.H.; Chen, T.L.; How, C.K.; Yang, Y.S.; Lee, Y.T. Community-acquired bloodstream infections caused by Acinetobacter baumannii: A matched case-control study. J. Microbiol. Immunol. Infect. 2018, 51, 629–635. [Google Scholar] [CrossRef]
  11. Wong, D.; Nielsen, T.B.; Bonomo, R.A.; Pantapalangkoor, P.; Luna, B.; Spellberg, B. Clinical and pathophysiological overview of Acinetobacter infections: A century of challenges. Clin. Microbiol. Rev. 2017, 30, 409–447. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Rangel, K.; Chagas, T.P.G.; De-Simone, S.G. Acinetobacter baumannii infections in times of COVID-19 pandemic. Pathogens 2021, 10, 1006. [Google Scholar] [CrossRef] [PubMed]
  13. Nodari, C.S.; Cayô, R.; Streling, A.P.; Lei, F.; Wille, J.; Almeida, M.S.; de Paula, A.I.; Pignatari, A.C.C.; Seifert, H.; Higgins, P.G.; et al. Genomic analysis of carbapenem-resistant Acinetobacter baumannii isolates belonging to major endemic clones in South America. Front. Microbiol. 2020, 11, 584603. [Google Scholar] [CrossRef] [PubMed]
  14. Wareth, G.; Linde, J.; Hammer, P.; Nguyen, N.H.; Nguyen, T.N.M.; Splettstoesser, W.D.; Makarewicz, O.; Neubauer, H.; Sprague, L.D.; Pletz, M.W. Phenotypic and WGS-derived antimicrobial resistance profiles of clinical and non-clinical Acinetobacter baumannii isolates from Germany and Vietnam. Int. J. Antimicrob. Agents 2020, 56, 106127. [Google Scholar] [CrossRef]
  15. Poirel, L.; Naas, T.; Nordmann, P. Diversity, epidemiology, and genetics of class D beta-lactamases. Antimicrob. Agents Chemother. 2010, 54, 24–38. [Google Scholar]
  16. Wong, M.H.-Y.; Chan, B.K.-W.; Chan, E.W.-C.; Chen, S. Over-expression of ISAba1-linked intrinsic and exogenously acquired OXA type carbapenem-hydrolyzing-class D-β-lactamase-encoding genes is key mechanism underlying carbapenem resistance in Acinetobacter baumannii. Front. Microbiol. 2019, 10, 2809. [Google Scholar] [CrossRef] [Green Version]
  17. Vázquez-López, R.; Solano-Gálvez, S.G.; Juárez Vignon-Whaley, J.J.; Abello Vaamonde, J.A.; Padró Alonzo, L.A.; Rivera Reséndiz, A.; Álvarez, M.M.; Vega López, E.N.; Franyuti-Kelly, G.; Álvarez-Hernández, D.A.; et al. Acinetobacter baumannii resistance: A real challenge for clinicians. Antibiotics 2020, 9, 205. [Google Scholar] [CrossRef]
  18. Ramirez, M.S.; Bonomo, R.A.; Tolmasky, M.E. Carbapenemases: Transforming Acinetobacter baumannii into a yet more dangerous menace. Biomolecules 2020, 10, 720. [Google Scholar] [CrossRef]
  19. Harding, C.M.; Hennon, S.W.; Feldman, M.F. Uncovering the mechanisms of Acinetobacter baumannii virulence. Nat. Rev. Microbiol. 2018, 16, 91–102. [Google Scholar] [CrossRef]
  20. Yang, C.H.; Su, P.W.; Moi, S.H.; Chuang, L.Y. Biofilm formation in Acinetobacter baumannii: Genotype-phenotype correlation. Molecules 2019, 24, 1849. [Google Scholar] [CrossRef] [Green Version]
  21. Asif, M.; Alvi, I.A.; Rehman, S.U. Insight into Acinetobacter baumannii: Pathogenesis, global resistance, mechanisms of resistance, treatment options, and alternative modalities. Infect. Drug Resist. 2018, 11, 1249–1260. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  22. Oikonomou, O.; Sarrou, S.; Papagiannitsis, C.C.; Georgiadou, S.; Mantzarlis, K.; Zakynthinos, E.; Dalekos, G.N.; Petinaki, E. Rapid dissemination of colistin and carbapenem resistant Acinetobacter baumannii in Central Greece: Mechanisms of resistance, molecular identification and epidemiological data. BMC Infect. Dis. 2015, 15, 559. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. Gupta, M.; Lakhina, K.; Kamath, A.; Vandana, K.E.; Mukhopadhyay, C.; Vidyasagar, S.; Varma, M. Colistin-resistant Acinetobacter baumannii ventilator-associated pneumonia in a tertiary care hospital: An evolving threat. J. Hosp. Infect. 2016, 94, 72–73. [Google Scholar] [CrossRef] [PubMed]
  24. Ilsan, N.A.; Lee, Y.J.; Kuo, S.C.; Lee, I.H.; Huang, T.W. Antimicrobial resistance mechanisms and virulence of colistin and carbapenem-resistant Acinetobacter baumannii isolated from a teaching Hospital in Taiwan. Microorganisms 2021, 9, 1295. [Google Scholar] [CrossRef] [PubMed]
  25. Kazmierczak, K.M.; Tsuji, M.; Wise, M.G.; Hackel, M.; Yamano, Y.; Echols, R.; Sahm, D.F. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem non- susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase producing isolates (SIDERO-WT-2014). Int. J. Antimicrob. Agents 2019, 53, 177–184. [Google Scholar] [CrossRef] [PubMed]
  26. Shapiro, A.B.; Moussa, S.H.; McLeod, S.M.; Durand-Réville, T.; Miller, A.A. Durlobactam, a new diazabicyclooctane β-lactamase inhibitor for the treatment of Acinetobacter infections in combination with sulbactam. Front. Microbiol. 2021, 12, 709974. [Google Scholar] [CrossRef]
  27. Petropoulou, D.; Siopi, M.; Vourli, S.; Pournaras, S. Activity of sulbactam-durlobactam and comparators against a national collection of carbapenem-resistant Acinetobacter baumannii isolates from Greece. Front. Cell. Infect. Microbiol. 2022, 11, 814530. [Google Scholar] [CrossRef]
  28. Di Popolo, A.; Giannouli, M.; Triassi, M.; Brisse, S.; Zarrilli, R. Molecular epidemiological investigation of multidrug-resistant Acinetobacter baumannii strains in four Mediterranean countries with a multilocus sequence typing scheme. Clin. Microbiol. Infect. 2011, 17, 197–201. [Google Scholar] [CrossRef] [Green Version]
  29. Levy-Blitchtein, S.; Roca, I.; Plasencia-Rebata, S.; Vicente-Taboada, W.; Velásquez-Pomar, J.; Muñoz, L.; Moreno-Morales, J.; Pons, M.J.; Del Valle-Mendoza, J.; Vila, J. Emergence and spread of carbapenem-resistant Acinetobacter baumannii international clones II and III in Lima, Peru. Emerg. Microbes Infect. 2018, 7, 119. [Google Scholar] [CrossRef] [Green Version]
  30. Kostyanev, T.; Xavier, B.B.; García-Castillo, M.; Lammens, C.; Bravo-Ferrer Acosta, J.; Rodríguez-Baño, J.; Cantón, R.; Glupczynski, Y.; Goossens, H.; EURECA/WP1B Group. Phenotypic and molecular characterizations of carbapenem-resistant Acinetobacter baumannii isolates collected within the EURECA study. Int. J. Antimicrob. Agents 2021, 57, 106345. [Google Scholar] [CrossRef]
  31. Rao, M.; Rashid, F.A.; Shukor, S.; Hashim, R.; Ahmad, N. Detection of antimicrobial resistance genes associated with carbapenem resistance from the whole-genome sequence of Acinetobacter baumannii isolates from Malaysia. Can. J. Infect. Dis. Med. Microbiol. 2020, 2020, 5021064. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  32. June, C.M.; Muckenthaler, T.J.; Schroder, E.C.; Klamer, Z.L.; Wawrzak, Z.; Powers, R.A.; Szarecka, A.; Leonard, D.A. The structure of a doripenem-bound OXA-51 class D β-lactamase variant with enhanced carbapenemase activity. Protein Sci. 2016, 25, 2152–2163. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  33. Kumburu, H.H.; Sonda, T.; van Zwetselaar, M.; Leekitcharoenphon, P.; Lukjancenko, O.; Mmbaga, B.T.; Alifrangis, M.; Lund, O.; Aarestrup, F.M.; Kibiki, G.S. Using WGS to identify antibiotic resistance genes and predict antimicrobial resistance phenotypes in MDR Acinetobacter baumannii in Tanzania. J. Antimicrob. Chemother. 2019, 74, 1484–1493. [Google Scholar] [CrossRef] [PubMed]
  34. Coyne, S.; Courvalin, P.; Périchon, B. Efflux-mediated antibiotic resistance in Acinetobacter spp. Antimicrob. Agents Chemother. 2011, 55, 947–953. [Google Scholar] [CrossRef] [Green Version]
  35. Yoon, E.J.; Courvalin, P.; Grillot-Courvalin, C. RND-type efflux pumps in multidrug-resistant clinical isolates of Acinetobacter baumannii: Major role for AdeABC overexpression and AdeRS mutations. Antimicrob. Agents Chemother. 2013, 57, 2989–2995. [Google Scholar] [CrossRef] [Green Version]
  36. Sun, X.; Ni, Z.; Tang, J.; Ding, Y.; Wang, X.; Li, F. The abaI/abaR quorum sensing system effects on pathogenicity in Acinetobacter baumannii. Front. Microbiol. 2021, 12, 679241. [Google Scholar] [CrossRef]
  37. Krasauskas, R.; Skerniškytė, J.; Armalytė, J.; Sužiedėlienė, E. The role of Acinetobacter baumannii response regulator BfmR in pellicle formation and competitiveness via contact-dependent inhibition system. BMC Microbiol. 2019, 19, 241. [Google Scholar] [CrossRef] [Green Version]
  38. Marr, C.M.; MacDonald, U.; Trivedi, G.; Chakravorty, S.; Russo, T.A. An evaluation of BfmR-regulated antimicrobial resistance in the extensively drug resistant (XDR) Acinetobacter baumannii Strain HUMC1. Front. Microbiol. 2020, 11, 595798. [Google Scholar] [CrossRef] [PubMed]
  39. Clemmer, K.M.; Bonomo, R.A.; Rather, P.N. Genetic analysis of surface motility in Acinetobacter baumannii. Microbiology 2011, 157, 2534–2544. [Google Scholar] [CrossRef] [Green Version]
  40. Partridge, S.R. Analysis of antibiotic resistance regions in Gram-negative bacteria. FEMS Microbiol. Rev. 2011, 35, 820–855. [Google Scholar] [CrossRef] [Green Version]
  41. Partridge, S.R.; Kwong, S.M.; Firth, N.; Jensen, S.O. Mobile genetic elements associated with antimicrobial resistance. Clin. Microbiol. Rev. 2018, 31, e00088-17. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  42. Abdi, S.N.; Ghotaslou, R.; Ganbarov, K.; Mobed, A.; Tanomand, A.; Yousefi, M.; Asgharzadeh, M.; Kafil, H.S. Acinetobacter baumannii efflux pumps and antibiotic resistance. Infect. Drug Resist. 2020, 13, 423–434. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  43. Corvec, S.; Caroff, N.; Espaze, E.; Giraudeau, C.; Drugeon, H.; Reynaud, A. AmpC cephalosporinase hyperproduction in Acinetobacter baumannii clinical strains. J. Antimicrob. Chemoth. 2003, 52, 629–635. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Corvec, S.; Poirel, L.; Naas, T.; Drugeon, H.; Nordmann, P. Genetics and expression of the carbapenem-hydrolyzing oxacillinase gene blaOXA-23 in Acinetobacter baumannii. Antimicrob. Agents Chemother. 2007, 51, 1530–1533. [Google Scholar] [CrossRef] [Green Version]
  45. Turton, J.F.; Ward, M.E.; Woodford, N.; Kaufmann, M.E.; Pike, R.; Livermore, D.M.; Pitt, T.L. The role of ISAba1 in expression of OXA carbapenemase genes in Acinetobacter baumannii. FEMS Microbiol. Lett. 2006, 258, 72–77. [Google Scholar] [CrossRef] [Green Version]
  46. Oh, M.H.; Choi, C.H.; Lee, J.C. The effect of ISAba1-mediated adeN gene disruption on Acinetobacter baumannii pathogenesis. Virulence 2017, 8, 1088–1090. [Google Scholar] [CrossRef] [Green Version]
  47. Mirzaei, R.; Goodarzi, P.; Asadi, M.; Soltani, A.; Aljanabi, H.A.A.; Jeda, A.S.; Dashtbin, S.; Jalalifar, S.; Mohammadzadeh, R.; Teimoori, A.; et al. Bacterial co-infections with SARS-CoV-2. UBMB Life 2020, 72, 2097–2111. [Google Scholar] [CrossRef]
  48. Elabbadi, A.; Turpin, M.; Gerotziafas, G.T.; Teulier, M.; Voiriot, G.; Fartoukh, M. Bacterial coinfection in critically ill COVID-19 patients with severe pneumonia. Infection 2021, 49, 559–562. [Google Scholar] [CrossRef]
  49. Shinohara, D.R.; Saalfeld, S.M.S.; Martinez, H.V.; Altafini, D.D.; Costa, B.B.; Fedrigo, N.H.; Tognim, M.C.B. Outbreak of endemic carbapenem-resistant Acinetobacter baumannii in a coronavirus disease 2019 (COVID-19)-specific intensive care unit. Infect. Cont. Hosp. Epidemiol. 2022, 43, 815–817. [Google Scholar] [CrossRef]
  50. Russo, A.; Gavaruzzi, F.; Ceccarelli, G.; Borrazzo, C.; Oliva, A.; Alessandri, F.; Magnanimi, E.; Pugliese, F.; Venditti, M. Multidrug-resistant Acinetobacter baumannii infections in COVID-19 patients hospitalized in intensive care unit. Infection 2022, 50, 83–92. [Google Scholar] [CrossRef]
  51. Piccirilli, A.; Perilli, M.; Piccirilli, V.; Segatore, B.; Amicosante, G.; Maccacaro, L.; Bazaj, A.; Naso, L.; Cascio, G.L.; Cornaglia, G. Molecular characterization of carbapenem-resistant Klebsiella pneumoniae ST14 and ST512 causing bloodstream infections in ICU and surgery wards of a tertiary university hospital of Verona (northern Italy): Co-production of KPC-3, OXA-48, and CTX-M-15 β-lactamases. Diagn. Microbiol. Infect. Dis. 2020, 96, 114968. [Google Scholar] [PubMed]
  52. Duan, N.; Sun, L.; Huang, C.; Li, X.; Cheng, B. Microbial distribution and antibiotic susceptibility of bloodstream infections in different intensive care unit. Front. Microbiol. 2021, 12, 792282. [Google Scholar] [CrossRef]
  53. CLSI. Principles and Procedures for Blood Cultures; Approved Guideline. CLSI document M47-A; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2007. [Google Scholar]
  54. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing, 30th ed.; CLSI supplement M100; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2020. [Google Scholar]
  55. Piccirilli, A.; Cherubini, S.; Azzini, A.M.; Tacconelli, E.; Lo Cascio, G.; Maccacaro, L.; Bazaj, A.; Naso, L.; Amicosante, G.; Ltcf-Veneto Working Group; et al. Whole-genome sequencing (WGS) of carbapenem-resistant K. pneumoniae isolated in Long-Term Care Facilities in the Northern Italian Region. Microorganisms 2021, 9, 1985. [Google Scholar] [CrossRef]
  56. Cherubini, S.; Perilli, M.; Azzini, A.M.; Tacconelli, E.; Maccacaro, L.; Bazaj, A.; Naso, L.; Amicosante, G.; LTCF-Veneto Working Group; Lo Lascio, G.; et al. Resistome and virulome of multi-drug resistant E. coli ST131 isolated from residents of Long-Term Care Facilities in the Northern Italian Region. Diagnostics 2022, 12, 213. [Google Scholar] [CrossRef] [PubMed]
  57. Wareth, G.; Linde, J.; Hammer, P.; Splettstoesser, W.D.; Pletz, M.W.; Neubauer, H.; Sprague, L.D. Molecular characterization of German Acinetobacter baumannii isolates and Multilocus Sequence Typing (MLST) analysis based on WGS reveals novel STs. Pathogens 2021, 10, 690. [Google Scholar] [CrossRef] [PubMed]
Table
Table 1. Antimicrobial resistance genes (ARGs) and mobile genetic elements (MGEs) in bloodstream (BSI) A. baumannii isolates.
Table 1. Antimicrobial resistance genes (ARGs) and mobile genetic elements (MGEs) in bloodstream (BSI) A. baumannii isolates.
StrainGenome Size (bp)MGEsΒ-Lactam
Resistance		Aminoglycoside ResistanceMacrolide
Resistance		Fluoroquinolone ResistanceOthers
A. baumannii PE1 (ST2)4,023,584Tn6207
ISEc29
ISAba26
IS26
ISAba125		blaADC-25
blaOXA-23
blaOXA-66		aadA1
aacA4
aph(3′)-VIa
aac(6′)Ib-cr
strB
strA
armA		mph(E)
msr(E)		aac(6′)Ib-crsul1
tet(B)
catB8
A. baumannii PE2 (ST2)4,023,635Tn6207
ISAba125
ISAba26
ISVsa3		blaADC-25
blaOXA-23
blaOXA-66		aadA1
aacA4
aph(3′)-VIa
aac(6′)Ib-cr
strB
strA
armA		mph(E)
msr(E)		aac(6′)Ib-crsul1
tet(B)
catB8
A. baumannii PE3 (ST2) 3,850,309ISEc29
ISAba125
ISAba2
ISAba13
IS17
IS6100		blaADC-25
blaOXA-23
blaOXA-82		aadA1
aacA2
aacA4
aadB
aph(3′)-Ic
aac(3)-Ia
armA		mph(E)
msr(E)		aac(6′)Ib-crsul1
catB8
A. baumannii PE4 (ST2)3,965,839Tn6207
ISVsa3
ISEc29
ISAba125
ISAba26		blaADC-25
blaOXA-23
blaOXA-66		aadA1
aacA4
strB
strA
armA		mph(E)
msr(E)		aac(6′)Ib-crsul1
tet(B)
catB8
A. baumannii PE5 (ST2)3,829,825ISEc29
ISAba125
ISAba2
ISAba13
IS17
IS6100		blaADC-25
blaOXA-23
blaOXA-82		aadA1
aacA2
aacA4
aadB
aph(3′)-VIa
aph(3′)-Ic
aac(3)-Ia
armA		mph(E)
msr(E)		aac(6′)Ib-crsul1
catB8
A. baumannii PE6 (ST2) 4,041,529Tn6207
ISVsa3
ISEc29
ISAba125
ISAba26
blaADC-25
blaOXA-23
blaOXA-66		aadA1
aacA4
strB
strA
armA		mph(E)
msr(E)		aac(6′)Ib-crsul1
tet(B)
catB8
A. baumannii PE7 (ST2)3,841,128ISEc29
ISAba125
ISAba2
ISAba13
IS17
IS6100		blaADC-25
blaOXA-23
blaOXA-82		aadA1
aacA2
aacA4
aadB
aph(3′)-VIa
aph(3′)-Ic
aac(3)-Ia
armA		mph(E)
msr(E)		aac(6′)Ib-crsul1
catB8
A. baumannii PE8 (ST2)3,852,243ISEc29
ISAba125
ISAba2
ISAba13
IS17
IS6100		blaADC-25
blaOXA-23
blaOXA-82		aadA1
aacA2
aacA4
aadB
aph(3′)-Ic
aac(3)-Ia
armA		mph(E)
msr(E)		aac(6′)Ib-crsul1
catB8
Table
Table 2. Virulence factors of the eight A. baumannii analyzed in this study.
Table 2. Virulence factors of the eight A. baumannii analyzed in this study.
CategoryVirulence FactorsRelated Genes
AdherenceOuter membrane proteinompA
Biofilm formationAdeFGH efflux pumpadeF; adeG; adeH
Biofilm-associated proteinbap
Csu fimbriaecsuA; csuB; csuC; csuD; csuE
Polysaccharide poly-N-acetylglucosaminepgaA; pgaB; pgaC; pgaD
EnzymePhospholipase Cplc
Phospholipase DplcD
Immune evasionLPSlpsB; lpxA; lpxB; lpxD; lpxL; lpxM
Iron uptakeAcinetobactinbarA; barB; basA; basB; basC; basD; basF; basG; basH; basI; basJ; bauA; bauB; bauC; bauD; bauE; bauF; entE;
Heme utilizationhemO
RegulationQuorum sensingabaI; abaR
Two-component system (BfmRS)bfmR; bfmS
Serum resistancePbpG (Penicillin-binding protein)pbpG
Stress adaptionCatalasekatA
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Cherubini, S.; Perilli, M.; Segatore, B.; Fazii, P.; Parruti, G.; Frattari, A.; Amicosante, G.; Piccirilli, A. Whole-Genome Sequencing of ST2 A. baumannii Causing Bloodstream Infections in COVID-19 Patients. Antibiotics 2022, 11, 955. https://doi.org/10.3390/antibiotics11070955

AMA Style

Cherubini S, Perilli M, Segatore B, Fazii P, Parruti G, Frattari A, Amicosante G, Piccirilli A. Whole-Genome Sequencing of ST2 A. baumannii Causing Bloodstream Infections in COVID-19 Patients. Antibiotics. 2022; 11(7):955. https://doi.org/10.3390/antibiotics11070955

Chicago/Turabian Style

Cherubini, Sabrina, Mariagrazia Perilli, Bernardetta Segatore, Paolo Fazii, Giustino Parruti, Antonella Frattari, Gianfranco Amicosante, and Alessandra Piccirilli. 2022. "Whole-Genome Sequencing of ST2 A. baumannii Causing Bloodstream Infections in COVID-19 Patients" Antibiotics 11, no. 7: 955. https://doi.org/10.3390/antibiotics11070955

APA Style

Cherubini, S., Perilli, M., Segatore, B., Fazii, P., Parruti, G., Frattari, A., Amicosante, G., & Piccirilli, A. (2022). Whole-Genome Sequencing of ST2 A. baumannii Causing Bloodstream Infections in COVID-19 Patients. Antibiotics, 11(7), 955. https://doi.org/10.3390/antibiotics11070955

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop